ArticleCancer medicine2019
Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.JNCI cancer spectrum · 2022Trial
- Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening.JAMA network open · 2026Article
- Lung cancer treatment pathways in the largest private health insurance in Brazil: a real-world data study.BMC cancer · 2026Article
- Budget Impact of the LungFlag™ Predictive Risk Model for Lung Cancer Screening.PharmacoEconomics - open · 2026Article
- Article
- Age-Based Screening for Lung Cancer Surveillance in the US.JAMA network open · 2025Article
- Nourishing lung health: a meta-analysis and systematic review protocol of nutrition interventions for lung cancer patients.Systematic reviews · 2025Article
- Patterns of Medical Care Cost by Service Type Associated With Lung Cancer Screening.Medical care · 2025Article
- Computed Tomographic Screening Intervals for Patients at Moderate Risk of Lung Cancer.JAMA network open · 2025Article
- Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Net Health System Costs of Parkinson Disease: A Propensity Score-Matched Health Administrative Data Cohort Study in Ontario, Canada.Neurology. Clinical practice · 2025Article
- Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2025Article
- Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study.BMC health services research · 2025Observational
- Article
- Assessment of the interval between diagnosis and definitive treatment of lung cancer at a public institution in São Paulo.Revista do Colegio Brasileiro de Cirurgioes · 2025Observational
- Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.International journal of clinical pharmacy · 2024Article
- Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions.Annals of the American Thoracic Society · 2024Article
- Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWe studied trends in lung cancer treatment cost over time by phase of care, treatment strategy, age, stage at diagnosis, and histology.
methodsUsing the Surveillance, Epidemiology, and End Results (SEER)-Medicare database for years 1998-2013, we allocated total and patient-liability costs into the following phases of care for 145 988 lung cancer patients: prediagnosis, staging, surgery, initial, continuing, and terminal. Patients served as self-controls to determine cancer-attributable costs based on individual precancer diagnosis healthcare costs. We fit linear regression models to determine cost by age and calendar year for each stage at diagnosis, histology, and treatment strategy and presented all costs in 2017 US dollars.
resultsMonthly healthcare costs prior to lung cancer diagnosis were $861 for a 70 years old in 2017 and rose by an average of $17 per year (P < 0.001). Surgery in 2017 cost $30 096, decreasing by $257 per year (P = 0.007). Chemotherapy and radiation costs remained stable or increased for most stage and histology groups, ranging from $4242 to $8287 per month during the initial six months of care. Costs during the final six months of life decreased for those who died of lung cancer or other causes.
conclusionsCost-effectiveness analyses of lung cancer control interventions in the United States have been using outdated and incomplete treatment cost estimates. Our cost estimates enable updated cost-effectiveness analyses to determine the benefit of lung cancer control from a health economics point of view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.